Ovarian Granulosa-Stromal Tumor clinical trials at University of California Health

1 research study open to eligible people

Showing trials for

  • Nirogacestat in Ovarian Granulosa Cell Tumors

    open to eligible females ages 18 years and up

    This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.

    at UCLA

Our lead scientists for Ovarian Granulosa-Stromal Tumor research studies include .

Last updated: